LEVOFLOXACIN | N021571 | SANTEN INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| N/A | Active | Turku University Hospital | 552 | 2017-04-03 → 2029-04-01 | |
| Phase 2 | Active | Boston University | 271 | 2022-06-07 → 2027-05 | |
| N/A | By Invitation | Turku University Hospital | 147 | 2017-08-09 → 2029-08-30 | |
| N/A | Not Yet Recruiting | Sylhet M.A.G.Osmani Medical College | 90 | 2026-08-01 → 2026-10-31 | |
| N/A | Not Yet Recruiting | The First Affiliated Hospital of Shihezi University | 350 | 2026-09-01 → 2027-12 | |
| Phase 3 | Not Yet Recruiting | Seoul National University Hospital | 294 | 2026-10-01 → 2032-06 | |
| Phase 2 | Not Yet Recruiting | University of Manitoba | 75 | 2026-09-01 → 2028-04-30 | |
| Phase 2/3 | Recruiting | Johns Hopkins University | 2,530 | 2026-05-08 → 2027-09 | |
| N/A | Recruiting | Groupe Hospitalier Diaconesses Croix Saint-Simon | 40 | 2023-06-10 → 2029-06 | |
| Phase 4 | Recruiting | Fundacion Clinic per a la Recerca Biomédica | 360 | 2022-08-17 → 2027-12-30 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
22 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Dec 4, 2014 | SUPPL -6 | View Letter (PDF) |
| Mar 2, 2004 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.